1. KD Tripathi. Drugs for Constipation and Diarrhoea. Essentials of Medical Pharmacology. Seventh edition. 2013. Page – 684.
2. Tilo Grosser, Emer Smyth and Garret A. Fitzgerald. Anti-inflammatory, Antipyretic, and analgesic agents; Pharmacotherapy of gout. Goodman & Gilman’s: The Pharmacological Basics of Therapeutics. 12 Edition. New York Mc Graw Hill Medical 2011. Page – 979.
3. Gerald G. Briggs, Roger K. Freeman. B. A reference guide to fetal and neonatal risk: Drugs in Pregnancy and Lactation. Tenth Edition. 2015. Page – 375-376.
4. Ferring Pharmaceuticals. Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC). NIH U.S. National Library of Medicine ClinicalTrials.gov. [Revised on April 2019] [Accessed 29th October 2020] https://clinicaltrials.gov/ct2/show/NCT02522767
5. Shire. Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects with Mild to Moderate Ulcerative Colitis (PACE). NIH U.S. National Library of Medicine ClinicalTrials.gov. [Revised on January 2020] [Accessed 29th October 2020] https://clinicaltrials.gov/ct2/show/NCT02093663
6. Bei Ye and Daniel R van Langenberg. Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal? NCBI; PMC National Library of Medicine, National Institute of Health. November 2015. [Accessed 29th October 2020] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635154/
7. Ferring GmbH. Electronic Medicines Compendium (EMC); [Revised on June 2015] [Accessed 29th October 2020] https://www.medicines.org.uk/emc/files/pil.6309.pdf